revenue $1.56B, net income $108.0M. Organon remediates material weaknesses, agrees to Sun Pharma acquisition

Filed July 31, 2026 · Period ending June 30, 2026 · Compared to 10-Q/A Nov 10, 2025 · ~1 min read

Key Changes

• high

  Sun Pharma to acquire all outstanding shares for $14.00 per share in cash; stockholder approval received July 23, 2026, closing expected early 2027.

  Notes: Sun Pharma acquisition agreement view on EDGAR →
• high

  Material weaknesses in tone-at-top and disclosure controls, identified in Q2 2025 following Nexplanon wholesaler sales investigation, fully remediated as of Q2 2026 after leadership changes and control enhancements.

  Controls & Procedures verify on EDGAR →
• high

  Nexplanon sales declined 12% H1 FY26 due to delayed reinsertions following five-year label approval and uncertainty around federal funding; company expects new label to offset headwind beginning H2 2026.

  MD&A: Nexplanon demand verify on EDGAR →